Development of a human papillomavirus (HPV) multiplex immunoassay to profile HPV antibodies

Abstract

AbstractNeutralizing antibodies (NAbs) are considered the primary mechanism of vaccine‐mediated protection against human papillomaviruses (HPV), the causative agent of cervical cancer. However, the minimum level of NAb needed for protection is currently unknown. The HPV pseudovirion‐based neutralization assay (PBNA) is the gold standard method for assessing HPV antibody responses but is time‐consuming and labor‐intensive. With the development of higher valency HPV vaccines, alternative serological assays with the capacity for multiplexing would improve efficiency and output. Here we describe a multiplex bead‐based immunoassay to characterize the antibody responses to the seven oncogenic HPV types (HPV16/18/31/33/45/52/58) contained in the current licensed nonavalent HPV vaccine. This assay can measure antibody isotypes and subclasses (total IgG, IgM, IgA1–2, IgG1–4), and can be adapted to measure other antibody features (e.g., Fc receptors) that contribute to vaccine immunity. When tested with serum samples from unvaccinated and vaccinated individuals, we found high concordance between HPV‐specific IgG using this multiplex assay and NAbs measured with PBNA. Overall, this assay is high‐throughput, sample‐sparing, and time‐saving, providing an alternative to existing assays for the measurement and characterization of HPV antibody responses.